Praxis Impact International ETF
PRXI - ETF AI Analysis
Top Page
Praxis Impact International ETF (PRXI)
PRXI, the Praxis Impact International ETF, has a solid overall rating driven by strong, diversified holdings like HSBC and Novartis, which show healthy financial performance, positive outlooks from earnings calls, and supportive technical trends. Healthcare leaders such as AstraZeneca and Roche also add quality, though their higher valuations and signs of potentially overbought conditions, along with mixed signals from names like SAP, slightly weigh on the fund’s rating. The main risk factor is its meaningful exposure to large, established companies where valuation and overbought technical conditions could limit future upside.
PRXI vs. SPDR S&P 500 ETF (SPY)
- AUM
- 6.89M
- Region
- Developed Markets
- Expense Ratio
- 0.54%
- Beta
- 0.52
- Issuer
- Praxis
- Inception Date
- Jun 24, 2026
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
PRXI Summary
Praxis Impact International ETF (PRXI) is an actively managed fund that invests in companies from developed countries outside North America, following a broad international stock market theme with a faith-based, values-driven approach. It holds well-known global names like Nestlé, Toyota, ASML, and HSBC, and spreads investments across many regions such as Japan, the UK, and Europe, and across sectors like financials, healthcare, and consumer goods. Someone might invest in PRXI to gain international diversification while aligning their money with their religious or ethical values. A key risk is that international stocks can go up and down with global markets and currency changes.
How much will it cost me?
This ETF has an expense ratio of 0.54%, which means you’ll pay about $5.40 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because PRXI is actively managed and uses a specialized, faith-based impact investing approach.
What would affect this ETF?
This ETF focuses on developed markets outside the U.S., so it could benefit if Europe and Japan see stronger economic growth, stable politics, and supportive central bank policies, especially for its large positions in technology, health care, and major global banks like HSBC and Mitsubishi UFJ. On the other hand, slower growth abroad, rising interest rates that hurt financials, currency swings versus the U.S. dollar, or new regulations and controversies that affect its faith-based screening or key holdings such as ASML, Roche, and Nestlé could weigh on future returns.
PRXI Top 10 Holdings
PRXI leans heavily on Europe and Japan, and its story starts with ASML, where earlier strength has cooled, leaving the chip giant more steady than soaring. Health care is a key engine: Roche and Novartis have been rising, giving the fund a solid defensive backbone, while AstraZeneca is losing steam and quietly holding returns back. Financials like HSBC and Mitsubishi UFJ are more mixed, with recent softness offset by longer‑term gains. Overall, the ETF feels broadly diversified but still anchored in European pharma and global financials.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 3.01% | $207.18K | EUR 511.40B | 51.88% | 76Outperform | |
| Roche Holding AG | ― | ― | ― | ― | 73Outperform | |
| Novartis AG | 1.60% | $110.52K | CHF 245.40B | 26.78% | 80Outperform | |
| HSBC Holdings | 1.60% | $109.89K | GBP 231.98B | 20.93% | 80Outperform | |
| AstraZeneca | ― | ― | ― | ― | 80Outperform | |
| Nestlé SA | 1.38% | $95.27K | CHF 225.64B | 8.18% | 71Outperform | |
| Mitsubishi UFJ Financial Group | 1.34% | $92.02K | JPY 39.11T | 41.84% | 76Outperform | |
| Toyota Motor | 1.25% | $86.12K | JPY 40.48T | 6.88% | 80Outperform | |
| SAP SE | 1.23% | $84.50K | EUR 249.22B | -2.13% | 66Neutral |
PRXI Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PRXI, the sentiment is Positive. The current price of 25.15 is above the 20-day moving average (MA) of 24.98, above the 50-day MA of 25.07, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 52.39 is Neutral, neither overbought nor oversold. The STOCH value of 58.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRXI.
PRXI Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $25.15 | $27.00(7.37% Upside) | $6.89M | 0.54% | 64Neutral | |
| $40.27 | $46.14(14.58% Upside) | $94.65M | 0.45% | 66Neutral | |
| $27.42 | $32.15(17.26% Upside) | $20.53M | 0.42% | 66Neutral | |
| $26.37 | ― | $20.46M | 0.99% | 67Neutral | |
| $30.80 | $37.50(21.75% Upside) | $18.53M | 0.55% | 66Neutral | |
| $24.90 | $34.19(37.33% Upside) | $9.94M | 0.35% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRXI | Praxis Impact International ETF | 25.15 | 0.78 | 3.19% | |
| INEQ | Columbia International Equity Income Etf | 40.27 | 5.63 | 16.25% | |
| RWIN | Rayliant NxtGen Multifactor International Equity ETF | 27.42 | 1.70 | 6.61% | |
| LCIV | Logan Capital International ETF | 26.37 | 1.54 | 6.20% | |
| FFDI | Fidelity Fundamental Developed International ETF | 30.80 | 1.94 | 6.73% | |
| JINT | Janus Henderson International Core Alpha ETF | 24.90 | -0.27 | -1.05% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
